Shouldn’t VIVUS Raise Capital Now? (VVUS)

While we have started mostly using The Wire at 247wallst.com for our biotech and active trader posts (among many other aspects 50 to 100 times per day), we have a question for BioHealthInvestor readers after VIVUS, Inc. (NASDAQ: VVUS) has basically doubled on news of Qnexa getting a recommendation for approval from a FDA panel… If [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]